Quantitative Evaluation of Retinal Vessel Density in Central Serous Chorioretinopathy after Half-dose Photodynamic Therapy

References

• Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology. 2010;117(9):1792–99. doi:10.1016/j.ophtha.2010.01.023.
   PubMed Web of Science ®Google Scholar
• Jirarattanasopa P, Ooto S, Tsujikawa A, Yamashiro K, Hangai M, Hirata M, Matsumoto A, Yoshimura N. Assessment of macular choroidal thickness by optical coherence tomography and angiographic changes in central serous chorioretinopathy. Ophthalmology. 2012;119(8):1666–78. doi:10.1016/j.ophtha.2012.02.021.
   PubMed Web of Science ®Google Scholar
• Yannuzzi LA. Type-A behavior and central serous chorioretinopathy. Retina. 1987;7(2):111–31. doi:10.1097/00006982-198700720-00009.
   PubMed Web of Science ®Google Scholar
• Breukink MB, Mohr JK, Ossewaarde-van Norel A, den Hollander AI, Keunen JE, Hoyng CB, Boon CJ. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol. Acta Ophthalmol. 2016;94(2):187–97. doi:10.1111/aos.12938.
   PubMed Web of Science ®Google Scholar
• Schwartz R, Habot-Wilner Z, Martinez MR, Nutman A, Goldenberg D, Cohen S, Shulman S, Guzner-Gur H, Loewenstein A, Goldstein M. Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study. Acta Ophthalmol. 2017;95(7):e610–e618. doi:10.1111/aos.13491.
   PubMed Web of Science ®Google Scholar
• Demirel S, Ozcan G, Yanik O, Batioglu F, Ozmert E. Vascular and structural alterations of the choroid evaluated by optical coherence tomography angiography and optical coherence tomography after half-fluence photodynamic therapy in chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2019;257:905–12. doi:10.1007/s00417-018-04226-6.
   PubMed Web of Science ®Google Scholar
• Zhao MW, Zhou P, Xiao HX, Lv YS, Li CA, Liu GD, Li XX. Photodynamic therapy for acute central serous chorioretinopathy: the safe effective lowest dose of verteporfin. Retina. 2009;29(8):1155–61. doi:10.1097/IAE.0b013e3181a6c028.
   PubMed Web of Science ®Google Scholar
• Zacks DN, Ezra E, Terada Y, Michaud N, Connolly E, Gragoudas ES, Miller JW. Verteporfin photodynamic therapy in the rat model of choroidal neovascularization: angiographic and histologic characterization. Invest Ophthalmol Vis Sci. 2002;43:2384–91.
   PubMed Web of Science ®Google Scholar
• Schlotzer-Schrehardt U, Viestenz A, Naumann GO, Laqua H, Michels S, Schmidt-Erfurth U. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol. 2002;240(9):748–57. doi:10.1007/s00417-002-0517-4.
   PubMed Web of Science ®Google Scholar
• Peyman GA, Kazi AA, Moshfeghi D, Unal M, Khoobehi B, Yoneya S, Mori K, Rivera I. Threshold and retreatment parameters of NPe6 photodynamic therapy in retinal and choroidal vessels. Ophthalmic Surg Lasers. 2000;31:323–27.
   PubMedGoogle Scholar
• Framme C, Flucke B, Birngruber R. Comparison of reduced and standard light application in photodynamic therapy of the eye in two rabbit models. Graefes Arch Clin Exp Ophthalmol. 2006;244(7):773–81. doi:10.1007/s00417-005-0221-2.
   PubMed Web of Science ®Google Scholar
• Mori K, Yoneya S, Ohta M, Sano A, Anzai K, Peyman GA, Moshfeghi DM. Angiographic and histologic effects of fundus photodynamic therapy with a hydrophilic sensitizer (mono-L-aspartyl chlorin e6). Ophthalmology. 1999;106(7):1384–91. doi:10.1016/S0161-6420(99)00729-0.
   PubMed Web of Science ®Google Scholar
• Canal-Fontcuberta I, Salomao DR, Robertson D, Cantrill HL, Koozekanani D, Rath PP, Pulido JS. Clinical and histopathologic findings after photodynamic therapy of choroidal melanoma. Retina. 2012;32(5):942–48. doi:10.1097/IAE.0b013e31825097c1.
   PubMed Web of Science ®Google Scholar
• Ren J, Li P, Zhao H, Chen D, Zhen J, Wang Y, Wang Y, Gu Y. Assessment of tissue perfusion changes in port wine stains after vascular targeted photodynamic therapy: a short-term follow-up study. Lasers Med Sci. 2014;29:781–88.
   PubMed Web of Science ®Google Scholar
• Izumi T, Koizumi H, Maruko I, Takahashi Y, Sonoda S, Sakamoto T, Iida T. Structural analyses of choroid after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy. Br J Ophthalmol. 2017;101(4):433–37. doi:10.1136/bjophthalmol-2016-308921.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Guo X, Ouyang P. Branch retinal artery occlusion associated with photodynamic therapy in a circumscribed choroidal haemangioma. Photodiagn Photodyn Ther. 2013;10(4):644–46. doi:10.1016/j.pdpdt.2013.07.004.
   PubMed Web of Science ®Google Scholar
• Nassisi M, Lavia C, Alovisi C, Musso L, Eandi CM. Short-term choriocapillaris changes in patients with central serous chorioretinopathy after half-dose photodynamic therapy. Int J Mol Sci. 2017;18:11. doi:10.3390/ijms18112468.
   Web of Science ®Google Scholar
• Kim HM, Park KH, Woo SJ. Massive exudative retinal detachment following photodynamic therapy and intravitreal bevacizumab injection in retinal capillary hemangioma. Korean J Ophthalmol. 2015;29(2):143–45. doi:10.3341/kjo.2015.29.2.143.
   PubMedGoogle Scholar
• Schmidt-Erfurth UM, Kusserow C, Barbazetto IA, Laqua H. Benefits and complications of photodynamic therapy of papillary capillary hemangiomas. Ophthalmology. 2002;109(7):1256–66. doi:10.1016/S0161-6420(02)01059-X.
   PubMed Web of Science ®Google Scholar
• Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa DL, Huang SJ, Klancnik JM Jr., Aizman A. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study 2003. Retina. 2012;32:288–98.
   PubMed Web of Science ®Google Scholar
• Feucht N, Maier M, Lohmann CP, Reznicek L. OCT angiography findings in acute central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging Retina. 2016;47(4):322–27. doi:10.3928/23258160-20160324-03.
   PubMed Web of Science ®Google Scholar
• Park KA, Oh SY. An optical coherence tomography-based analysis of choroidal morphologic features and choroidal vascular diameter in children and adults. Am J Ophthalmol. 2014;158(4):716–723 e712. doi:10.1016/j.ajo.2014.07.008.
   PubMed Web of Science ®Google Scholar
• Min JY, Lv Y, Yu S, Gong YY. Findings of OCT-angiography compared to fluorescein and indocyanine green angiography in central serous chorioretinopathy. Lasers Surg Med. 2018;50(10):987–93. doi:10.1002/lsm.22952.
   PubMed Web of Science ®Google Scholar
• Cakir B, Reich M, Lang S, Buhler A, Ehlken C, Grundel B, Stech M, Reichl S, Stahl A, Bohringer D, et al. OCT angiography of the choriocapillaris in central serous chorioretinopathy: a quantitative subgroup analysis. Ophthalmol Ther. 2019;8:75–86.
   Web of Science ®Google Scholar
• Demircan A, Yesilkaya C, Alkin Z. Early choriocapillaris changes after half-fluence photodynamic therapy in chronic central serous chorioretinopathy evaluated by optical coherence tomography angiography: preliminary results. Photodiagnosis Photodyn Ther. 2018;21:375–78. doi:10.1016/j.pdpdt.2018.01.015.
   PubMed Web of Science ®Google Scholar
• Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Arch Ophthalmol. 1999;117(10):1329–45. doi:10.1001/archopht.117.10.1329.
   PubMed Web of Science ®Google Scholar
• Saperstein DA, Rosenfeld PJ, Bressler NM, Rosa RH Jr., Sickenberg M, Sternberg P Jr., Aaberg TM Sr., Aaberg TM Jr., Reaves TA; Verteporfin in Ocular Histoplasmosis Study G. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series. Ophthalmology. 2002;109(8):1499–505. doi:10.1016/S0161-6420(02)01103-X.
   PubMed Web of Science ®Google Scholar
• van Rijssen TJ, van Dijk EHC, Yzer S, Ohno-Matsui K, Keunen JEE, Schlingemann RO, Sivaprasad S, Querques G, Downes SM, Fauser S, et al. Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res. 2019;73:100770. doi:10.1016/j.preteyeres.2019.07.003.
   PubMed Web of Science ®Google Scholar
• Cheng CK, Chang CK, Peng CH. Comparison of photodynamic therapy using half-dose of verteporfin or half-fluence of laser light for the treatment of chronic central serous chorioretinopathy. Retina. 2017;37(2):325–33. doi:10.1097/IAE.0000000000001138.
   PubMed Web of Science ®Google Scholar
• Maruko I, Iida T, Sugano Y, Ojima A, Sekiryu T. Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy. Retina. 2011;31(8):1603–08. doi:10.1097/IAE.0b013e31820f4b39.
   PubMed Web of Science ®Google Scholar
• Ding X, Li J, Zeng J, Ma W, Liu R, Li T, Yu S, Tang S. Choroidal thickness in healthy Chinese subjects. Invest Ophthalmol Vis Sci. 2011;52(13):9555–60. doi:10.1167/iovs.11-8076.
   PubMed Web of Science ®Google Scholar